The team's goal is to maximize the recruitment of endogenous harness T cells selectively against tumor cells using multiple low affinity tumor antigen and immune cell binding interactions. Given its potential high selectivity for cancer cells that express higher copy numbers of a target tumor antigen compared to healthy cells, this therapeutic strategy can achieve a much larger therapeutic window enabling for prolonged duration of anti-tumor response with markedly reduced side effects. Their work is funded by Prostate Cancer Canada as part of the 2019 Discovery Grant program, and we are excited to see where this collaboration leads!